Cargando…
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
Malignant melanoma of the uvea is remarkable for purely haematogenous dissemination and its tendency to metastasise to the liver. Although the liver is involved in up to 95% of patients, 50% of these also develop extrahepatic metastases, most often in the lungs, bone, skin, and brain. The only effec...
Autores principales: | Becker, J C, Terheyden, P, Kämpgen, E, Wagner, S, Neumann, C, Schadendorf, D, Steinmann, A, Wittenberg, G, Lieb, W, Bröcker, E-B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376169/ https://www.ncbi.nlm.nih.gov/pubmed/12373596 http://dx.doi.org/10.1038/sj.bjc.6600521 |
Ejemplares similares
-
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993) -
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013) -
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study
por: Guida, Michele, et al.
Publicado: (2010) -
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016) -
Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
por: Vetter, C S, et al.
Publicado: (2004)